Prescribing without an in-person exam: the state examination rules

The short answer depends on the drug and the state

Two separate rule systems decide this, and both matter. First, the state where your patient sits sets the standard of care for whether a video-only intake can establish a prescribing relationship — and states differ on whether a prior in-person exam is required 1Ref 1U.S. Department of Health and Human Services (2026).Licensure — Telehealth policy.The rule that the patient's state sets the standard of care and licensure for a telehealth prescribing relationship.. Second, if the medication is a controlled substance, a federal DEA telemedicine regime governs on top of the state rule, and its current flexibilities are an extension, not a permanent rule, as of July 2026 2Ref 2U.S. Department of Health and Human Services (2026).Prescribing controlled substances via telehealth.The current extended DEA/HHS telemedicine regime for prescribing controlled substances, as of July 2026..

So the honest answer is rarely a flat yes or no. It is: which state is the patient in, and is this a controlled substance? Answer those two, and the rule you have to follow falls out of them.

Non-controlled medications: the standard-of-care question

For medications that are not controlled substances, most states let a real-time audio-video intake establish the prescriber-patient relationship, provided the visit meets that state's standard of care — the same clinical adequacy a first in-person visit would require. What varies is whether the state demands a prior or periodic in-person examination, how it defines an adequate telehealth evaluation, and whether any exceptions attach to specific drug classes. The patient's state, not yours, sets that bar 1Ref 1U.S. Department of Health and Human Services (2026).Licensure — Telehealth policy.The rule that the patient's state sets the standard of care and licensure for a telehealth prescribing relationship..

The practical move is to read the destination state's telehealth or medical-practice rule for the phrase that matters — whether a valid prescriber-patient relationship can be established by telehealth alone — before you write. Where it can, document the evaluation as you would any first visit; where it cannot, plan the required in-person step into the intake rather than discovering it after prescribing.

Controlled substances: the DEA telemedicine regime

Controlled substances carry an extra federal layer. The in-person requirement that ordinarily precedes a controlled-substance prescription has been waived under pandemic-era telemedicine flexibilities that DEA and HHS have repeatedly extended — an extension regime under active rulemaking, current as of July 2026, not a settled permanent rule 2Ref 2U.S. Department of Health and Human Services (2026).Prescribing controlled substances via telehealth.The current extended DEA/HHS telemedicine regime for prescribing controlled substances, as of July 2026.. Because the rule is being revised, check the DEA Diversion Control Division for the version in force before you prescribe a controlled substance after a video-only intake 3Ref 3Drug Enforcement Administration (2026).Diversion Control Division.That DEA's Diversion Control Division administers registration, EPCS, and controlled-substance recordkeeping..

Two things stay true regardless of the current flexibility window:

• Cross-border prescriptions still require authority to practice in the patient's state — the DEA regime governs the in-person question, not the licensure one.
• Some drug classes and some states impose additional limits on remote initiation, so confirm both the federal posture and the destination state's rule before initiating controlled substances by telehealth rather than assuming a single national answer.

What counts as an adequate exam varies by state

'Video-only' is not one thing. States differ on what makes a telehealth evaluation adequate to prescribe: some accept a real-time audio-video encounter as fully equivalent to an in-person visit, some require synchronous video specifically (ruling out audio-only for initiation), and some layer conditions for particular medications or diagnoses. Because the patient's state sets this, the same video intake can be sufficient in one state and short of the bar in the next 1Ref 1U.S. Department of Health and Human Services (2026).Licensure — Telehealth policy.The rule that the patient's state sets the standard of care and licensure for a telehealth prescribing relationship..

That variability is why a portable checklist beats a memorized rule. For each state you practice in, note three things: can a prescribing relationship be established by telehealth alone, is synchronous video required, and are there drug-specific carve-outs. Keep it with your intake workflow, and revisit it when a state updates its telehealth statute.

The platform and EPCS mechanics

The visit has to run on a HIPAA-compliant, real-time audio-video platform, now that the COVID-era enforcement discretion for non-compliant tools has ended — the OCR telehealth guidance is the reference for what qualifies and when a business associate agreement is needed 4Ref 4HHS Office for Civil Rights (2026).HIPAA and Telehealth.That telehealth must run on HIPAA-compliant arrangements with OCR guidance on platforms and BAAs.. If you prescribe controlled substances, the e-prescribing standard — electronic prescribing of controlled substances, or EPCS — and DEA recordkeeping rules apply to how those prescriptions leave your system, administered through the DEA Diversion Control Division 3Ref 3Drug Enforcement Administration (2026).Diversion Control Division.That DEA's Diversion Control Division administers registration, EPCS, and controlled-substance recordkeeping..

Running this from an officeless practice is common and fully workable, but the platform, the business associate agreement, and the EPCS setup are the pieces that make a video-only prescribing workflow defensible — not the physical room you sit in. Get those three in place before the first prescribing visit, not after.

Medicare's in-person-visit rule for behavioral-health telehealth

For Medicare behavioral-health telehealth specifically, Congress and CMS built in an in-person-visit condition that has been amended and delayed over time — the requirement that a beneficiary be seen in person within a defined window around telehealth mental-health services, as reflected in the Medicare telehealth booklet 5Ref 5Centers for Medicare & Medicaid Services (2025).Telehealth Services.The Medicare behavioral-health telehealth in-person-visit condition as reflected in the MLN booklet.. Whether it is in force, and on what timeline, has shifted with each extension, so treat it as a moving date and confirm the current rule 6Ref 6U.S. Department of Health and Human Services (2026).Telehealth policy.The federal telehealth policy state — which flexibilities are permanent vs temporary — as of July 2026..

For a solo prescriber who bills Medicare, that means the in-person condition is a calendar item to track per patient, not a one-time setup fact. Note the current window when you onboard a Medicare patient, and re-check it whenever the flexibilities are extended again, because the date that governs your documentation can move underneath an active caseload.

Documenting a defensible video-only intake

Whatever the state and drug allow, the record is what proves you met the standard. A defensible video-only prescribing intake documents the same clinical substance an in-person first visit would — history, examination to the extent telehealth permits, assessment, and plan — plus the pieces telehealth adds: the patient's verified location, the informed consent to a telehealth visit, and the platform used. The note should make clear why a video evaluation was clinically adequate for this patient.

Concretely, keep these in the intake record:

• The patient's physical location at the time of the visit, confirmed at the start.
• Documented informed consent to receive care by telehealth, per the patient's state rule.
• The history and evaluation supporting the diagnosis and the prescription.
• For controlled substances, the identity verification and any DEA-regime requirements in force at the time.
• The platform used and confirmation it meets HIPAA requirements.

None of this is exotic; it is the ordinary chart, adapted so that if a board or payer ever asks why you prescribed after a video visit, the answer is already written down.